Department of Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX.
Department of Health Services Research, MD Anderson Cancer Center, Houston, TX.
Chest. 2018 Feb;153(2):438-452. doi: 10.1016/j.chest.2017.08.026. Epub 2017 Aug 31.
Guidelines for recurrent malignant pleural effusions (MPEs) recommend definitive procedures, such as indwelling pleural catheters (IPCs) or pleurodesis, over repeat thoracentesis. We hypothesized that many patients have multiple thoracenteses rather than definitive procedures and that this results in more procedures and complications.
Retrospective cohort study using SEER-Medicare data from 2007 to 2011. Patients 66 to 90 years of age with an MPE were included. The primary outcome was whether patients with rapidly recurring MPE, defined as recurrence within 2 weeks of first thoracentesis, received guideline consistent care. Guideline consistent care was defined as a definitive second pleural procedure.
Thoracentesis for MPE was performed in 23,431 patients. A second pleural procedure because of recurrence was required in 12,967 (55%). Recurrence was rapid in 7,565 (58%) of the 12,967 patients that had a recurrence. Of the 7,565 patients with rapid recurrence, 1,811 (24%) received guideline consistent care. Definitive pleural procedures compared with repeat thoracentesis resulted in fewer subsequent pleural procedures (0.62 vs 1.44 procedures per patient, respectively; P < .0001), fewer pneumothoraxes (< 0.0037 vs 0.009 pneumothoraxes per patient, respectively; P = .001), and fewer ED procedures (0.02 vs 0.04 ED procedures per patient, respectively; P < .001). Repeat thoracentesis and IPCs resulted in fewer inpatient days compared with chest tube or thoracoscopic pleurodesis (0.013 vs 0.013 vs 0.085 vs 0.097 inpatient days per day of life, respectively; P < .001).
Guideline consistent care using definitive procedures compared with repeat thoracentesis was associated with fewer subsequent procedures and complications; however, pleurodesis resulted in more inpatient days.
复发性恶性胸腔积液(MPE)指南建议采用留置胸腔导管(IPC)或胸膜固定术等确定性治疗方法,而不是重复胸腔穿刺术。我们假设许多患者进行多次胸腔穿刺术而不是确定性治疗,这会导致更多的治疗操作和并发症。
这是一项使用 2007 年至 2011 年 SEER-Medicare 数据的回顾性队列研究。纳入年龄在 66 至 90 岁之间且患有 MPE 的患者。主要结局是快速复发性 MPE 患者(首次胸腔穿刺后 2 周内复发)是否接受了符合指南的治疗。符合指南的治疗定义为进行第二次胸膜治疗。
共有 23431 例患者接受胸腔穿刺术治疗 MPE。12967 例(55%)因复发需要进行第二次胸膜治疗。在 12967 例复发患者中,7565 例(58%)复发迅速。在 7565 例快速复发的患者中,1811 例(24%)接受了符合指南的治疗。与重复胸腔穿刺术相比,确定性胸膜治疗可减少后续胸膜治疗次数(0.62 次 vs 1.44 次/患者,P<0.0001)、气胸(0.0037 次 vs 0.009 次/患者,P=0.001)和急诊就诊次数(0.02 次 vs 0.04 次/患者,P<0.001)。与胸腔引流管或胸腔镜胸膜固定术相比,重复胸腔穿刺术和 IPC 可减少住院天数(0.013 天 vs 0.013 天 vs 0.085 天 vs 0.097 天/生存天数,P<0.001)。
与重复胸腔穿刺术相比,采用确定性治疗方法的符合指南的治疗与减少后续治疗操作和并发症相关,但胸膜固定术会导致更多的住院天数。